TY  - JOUR
AU  - Puente, Javier
AU  - Anido, Urbano
AU  - Climent, Miguel Angel
AU  - Gonzalez-Billalabeitia, Enrique
AU  - Lainez, Nuria
AU  - Lambea, Julio
AU  - Maroto, Jose Pablo
AU  - Mendez-Vidal, Maria Jose
AU  - Montesa, Alvaro
AU  - Rodriguez, Angel
AU  - Zambrana, Curro
AU  - Gonzalez-Del-Alba, Aranzazu
PY  - 2020
DO  - 10.1177/1758835920920067
SN  - 1758-8340
UR  - https://hdl.handle.net/10668/26709
T2  - Therapeutic advances in medical oncology
AB  - Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. Systematic...
LA  - en
PB  - Sage Publications
KW  - Abiraterone acetate
KW  - Androgen-deprivation therapy
KW  - Chemotherapy
KW  - Enzalutamide
KW  - Metastatic castration-resistant prostate cancer
KW  - Radium-223
KW  - Docetaxel
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Androgen Antagonists
KW  - Evidence-Based Medicine
KW  - Medical Oncology
TI  - Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE.
TY  - research article
VL  - 12
ER  -